Lomexa0.3%

Lomexa 0.3% ophthalmic preparation is indicated in the bacterial infections, including conjunctivitis, blepharitis, blepharoconjunctivitis which are due to Lomexa 0.3% susceptible germs and Staphylococcus aureus- induced corneal ulcers.

4-Quinolone preparations, Ophthalmic antibacterial drugs

Lomexa 0.3%, a difluorinated quinolone derivative, is a bacterial gyrase inhibitor, effective against gram positive and gram negative bacteria. The acute toxicity of Lomexa 0.3% following systemic and topical ophthalmic application is low. Lomexa 0.3% interferes with bacterial DNA related processes like initiation, elongation, and termination phases of replication, transcription, DNA repairing, recombination, transposition, supercoiling and relaxation of DNA. The target molecule for quinolones is the A-subunit of bacterial enzyme gyrase (topoisomerase II). The forming of a stable complex between the quinolone and the whole gyrase teramer A2B2 leads to impaired enzyme functions, resulting in a rapid killing of sensitive bacteria.Cross-resistance has only been reported with other quinolones, but not with any other group of antibiotics. No clinical studies are available about the efficacy in cases of infections with chlamydia.

Adults and children (above 1 year of age): Instill 2-3 times daily 1 drop into the lower conjunctival sac. At the beginning of the treatment application should be more frequent, apply 5 drops within 20 minutes or 1 drop every hour during 6-10 hours. Duration of the treatment: 7 to 9 days.

May be taken with or without food.

In order to avoid reduction of efficacy, no ophthalmic preparations containing heavy metals, such as zinc, should be used during 15 minutes preceding and following application of Lomexa 0.3%. Bacteriostatic ophthalmic antibiotics should not be used concomitantly with Lomexa 0.3% eye drops.

Hypersensitivity to the active ingredient, to excipients, or to quinolones. Long term treatment with antibiotics may enhance development of secondary fungal infections or may support growth of non susceptible bacteria.

Slight and transient burning immediately after instillation of the eye drops has been reported in 4.7% of users. Although phototoxicity has not been reported after ophthalmic use, photosensitization is possible. Since the following allergic reactions have been reported after systemic use of Lomexa 0.3%, they can not be excluded after topical ophthalmic use: allergic reactions, asthma, dyspnoea, urticaria, erythema, pruritus, and hypersensitization.

Animal studies revealed that after systemic use of 20 mg/kg, Lomexa 0.3% passes the placenta barrier and is excreted into the maternal milk. Clinical studies on the use of Lomexa 0.3% eye drops during human pregnancy or lactation are not available. Therefore, the drug should only be used when the benefit outweighs the potential risk for the foetus or the infant.

Some isolated cases of phototoxicity have been reported after systemic but not after topical ophthalmic use of Lomexa 0.3%. Nevertheless, during treatment with Lomexa 0.3% intensive exposure to sunlight or UV-radiation should be avoided

Practically there is no risk of adverse effects due to accidental oral ingestion, since a bottle of 5 ml eye drop solution contains only 15 mg Lomexa 0.3%. This corresponds to 3.75% of the recommended oral daily dose for adults of 400 mg Lomexa 0.3%.

Store at 15-25° C

4-Quinolone preparations, Ophthalmic antibacterial drugs

Lomexa 0.3%, a difluorinated quinolone derivative, is a bacterial gyrase inhibitor, effective against gram positive and gram negative bacteria. The acute toxicity of Lomexa 0.3% following systemic and topical ophthalmic application is low. Lomexa 0.3% interferes with bacterial DNA related processes like initiation, elongation, and termination phases of replication, transcription, DNA repairing, recombination, transposition, supercoiling and relaxation of DNA. The target molecule for quinolones is the A-subunit of bacterial enzyme gyrase (topoisomerase II). The forming of a stable complex between the quinolone and the whole gyrase teramer A2B2 leads to impaired enzyme functions, resulting in a rapid killing of sensitive bacteria.Cross-resistance has only been reported with other quinolones, but not with any other group of antibiotics. No clinical studies are available about the efficacy in cases of infections with chlamydia.

Animal studies revealed that after systemic use of 20 mg/kg, Lomexa 0.3% passes the placenta barrier and is excreted into the maternal milk. Clinical studies on the use of Lomexa 0.3% eye drops during human pregnancy or lactation are not available. Therefore, the drug should only be used when the benefit outweighs the potential risk for the foetus or the infant.